Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/101025
DC FieldValueLanguage
dc.contributor.authorCarvalho, João-
dc.contributor.authorNunes, Pedro-
dc.contributor.authorSilva, Edgar Tavares da-
dc.contributor.authorSilva, Rodolfo-
dc.contributor.authorLima, João-
dc.contributor.authorQuaresma, Vasco-
dc.contributor.authorFigueiredo, Arnaldo-
dc.date.accessioned2022-07-26T09:12:01Z-
dc.date.available2022-07-26T09:12:01Z-
dc.date.issued2021-03-18-
dc.identifier.issn2282-4197pt
dc.identifier.issn1124-3562pt
dc.identifier.urihttp://hdl.handle.net/10316/101025-
dc.description.abstractObjectives: Clinical approach of prostate cancer (PCa) biochemical recurrence (BCR) is an ever-changing topic. Prostate-specific membrane antigen positron emission tomography ([68Ga]Ga-PSMA-11 PET-CTPSMA PET-CT) has shown good potential in this field. The aim is to evaluate PSMA PET-CT detection rate in PCa BCR and assess its impact on clinical outcome. Material and methods: Out of 319 patients with PCa who underwent PSMA PET-CT between October 2015 and June 2019, 70 had developed BCR after treatment with curative intent. Two groups were created: one with BCR after surgery (RP group) (N: 48; 68.6%) and other with BCR after radiotherapy (RT group) (N: 22; 31.4%). Clinical, analytical, pathological and PSMA PET-CT results were evaluated. Results: Initial age was different between groups (p = 0.008). RP patients were mainly at intermediate risk (85.1% vs 42.9%, p = 0.001) while RT patients were at low risk of recurrence (8.5% vs 47.6%, p = 0.001). In RP and RT groups, PSMA PETCT detected, respectively, pelvic relapse in 31.3% and 63.6%, and extrapelvic relapse in 18.8% and 31.8%. Salvage treatment was performed in 61.9% (n = 26) of RP patients and in 15% (n = 3) of RT patients, p < 0.001. Of RP patients submitted to salvage treatment, 59.1% achieved complete remission. Concerning these patients, local radiotherapy led to complete remission in 68.4% (n = 13). Of RT patients submitted to salvage treatment, two had complete remission and one had partial remission.Concerning detection rate, PSMA PET-CT was positive for pelvic relapse when pre-PET PSA ≥ 0.8 ng/mL (RP) or ≥ 2.3 ng/mL (RT) and for extrapelvic relapse when PSA ≥ 0.4 ng/mL (RP) or ≥ 3.5 ng/mL (RT), p > 0.05. Conclusions: Biochemical persistence rate after salvage therapy was similar (30-40%). The cut-off PSA values for pelvic relapse detected on PSMA PET-CT were ≥ 0.8 ng/mL (RP) and ≥ 2.3 ng/mL (RT).pt
dc.language.isoengpt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt
dc.subject.meshAgedpt
dc.subject.meshCross-Sectional Studiespt
dc.subject.meshHumanspt
dc.subject.meshMalept
dc.subject.meshMiddle Agedpt
dc.subject.meshNeoplasm Recurrence, Localpt
dc.subject.meshProstate-Specific Antigenpt
dc.subject.meshProstatic Neoplasmspt
dc.subject.meshGallium Isotopespt
dc.subject.meshGallium Radioisotopespt
dc.subject.meshPositron Emission Tomography Computed Tomographypt
dc.subject.meshRadiopharmaceuticalspt
dc.title[68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patientspt
dc.typearticle-
degois.publication.firstPage21pt
degois.publication.lastPage25pt
degois.publication.issue1pt
degois.publication.titleArchivio Italiano di Urologia e Andrologiapt
dc.peerreviewedyespt
dc.identifier.doi10.4081/aiua.2021.1.21pt
degois.publication.volume93pt
dc.date.embargo2021-03-18*
uc.date.periodoEmbargo0pt
item.fulltextCom Texto completo-
item.grantfulltextopen-
item.languageiso639-1en-
crisitem.author.orcid0000-0002-3038-0492-
crisitem.author.orcid0000-0002-4538-199X-
crisitem.author.orcid0000-0002-7157-0081-
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
Show simple item record

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons